| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/30/2013 | CA2696948C 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| 04/30/2013 | CA2692761C Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation |
| 04/30/2013 | CA2673249C 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| 04/30/2013 | CA2672250C Antiviral indoles |
| 04/30/2013 | CA2662919C Pharmaceutical compositions containing rosuvastatin calcium |
| 04/30/2013 | CA2620175C Disinfectant with quaternary ammonium polymers and copolymers |
| 04/30/2013 | CA2608639C Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate |
| 04/30/2013 | CA2602553C 2,4,8-trisubstituted 8h-pyrido[2,3-d]pyrimidin-7-one derivatives, compositions thereof, and uses thereof |
| 04/30/2013 | CA2602089C Tigecycline compositions and methods of preparation |
| 04/30/2013 | CA2601129C Crystallisation and purification of glycopyrronium bromide |
| 04/30/2013 | CA2599425C Substituted gamma lactams as therapeutic agents |
| 04/30/2013 | CA2595834C Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
| 04/30/2013 | CA2589289C Use of (-)-1-(benzofuran-2-yl)-2-propylaminopentane to treat substance dependence |
| 04/30/2013 | CA2584567C Pyrazolo (1,5-alpha) pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists |
| 04/30/2013 | CA2584342C Improved inhibitors for the soluble epoxide hydrolase |
| 04/30/2013 | CA2582180C Indazoles, benzisoxazoles and benzisothiazoles, process for preparing them, pharmaceutical compositions and use as estrogenic agents |
| 04/30/2013 | CA2579756C Modulators of central nervous system neurotransmitters |
| 04/30/2013 | CA2579199C Substituted isoxazoles as fungicides |
| 04/30/2013 | CA2571487C Pyrrazolo-pyrimidine derivatives |
| 04/30/2013 | CA2570606C Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| 04/30/2013 | CA2530494C Formulations for the treatment of arthritis conditions |
| 04/30/2013 | CA2517256C Aminoheteroaryl compounds as protein kinase inhibitors |
| 04/30/2013 | CA2514921C Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension |
| 04/30/2013 | CA2486303C Histone deacetylase inhibitors based on alpha-ketoepoxide compounds |
| 04/30/2013 | CA2458995C Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 04/30/2013 | CA2452491C Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 04/30/2013 | CA2435664C Ncc2705-the genome of a bifidobacterium |
| 04/30/2013 | CA2431483C Antiviral agents |
| 04/30/2013 | CA2417495C Methods for treating cell proliferative disorders and viral infections |
| 04/30/2013 | CA2412612C Eg-vegf nucleic acids and polypeptides and methods of use |
| 04/25/2013 | WO2013059791A2 Methods and compositions for promoting axon regeneration and nerve function |
| 04/25/2013 | WO2013059772A1 Enzyme inhibitor for cancer treatment |
| 04/25/2013 | WO2013059768A1 Therapeutic agents for treating gastrointestinal disorders associated with inflammation of the gastrointestinal tract |
| 04/25/2013 | WO2013059753A1 Therapeutic combination for the treatment of cancer |
| 04/25/2013 | WO2013059738A2 Use of inhibitors of bruton's tyrosine kinase (btk) |
| 04/25/2013 | WO2013059702A1 Cerivastatin to treat pulmonary disorders |
| 04/25/2013 | WO2013059677A1 Compounds that modulate intracellular calcium |
| 04/25/2013 | WO2013059666A1 Compounds that modulate intracellular calcium |
| 04/25/2013 | WO2013059651A1 Bifunctional compounds |
| 04/25/2013 | WO2013059642A1 Methods and compositions for attenuating tnf-a-mediated monocyte-endothelial interaction and improved flow-mediated vasodilation in hyperlipidemia using hops tetrahydro iso-alpha acids and niacin |
| 04/25/2013 | WO2013059638A1 Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| 04/25/2013 | WO2013059634A1 Use of cdk9 inhibitors to reduce cartilage degradation |
| 04/25/2013 | WO2013059631A1 Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4] oxazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine |
| 04/25/2013 | WO2013059630A1 Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| 04/25/2013 | WO2013059629A1 Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| 04/25/2013 | WO2013059610A1 Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
| 04/25/2013 | WO2013059606A1 Compounds and methods for the treatment of muscular disease, and related screening methods |
| 04/25/2013 | WO2013059592A1 Excipients for nicotine-containing therapeutic compositions |
| 04/25/2013 | WO2013059587A1 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| 04/25/2013 | WO2013059582A2 Small molecule inhibitors of histone deacteylases |
| 04/25/2013 | WO2013059548A1 Compositions and methods for treating cancer using jak2 inhibitor |
| 04/25/2013 | WO2013059485A1 Pyridopyrimidinone inhibitors of kinases |
| 04/25/2013 | WO2013059437A1 Inhibitors of arginase and their therapeutic applications |
| 04/25/2013 | WO2013059433A2 Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer |
| 04/25/2013 | WO2013059396A2 Treatment of cancer with tor kinase inhibitors |
| 04/25/2013 | WO2013059320A1 Treatment of cancers with mutant npm1 with mek inhibitors |
| 04/25/2013 | WO2013059295A2 Polymeric depots for localization of an agent to biological sites |
| 04/25/2013 | WO2013059265A1 A compound for the treatment of hepatitis c |
| 04/25/2013 | WO2013059245A1 Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| 04/25/2013 | WO2013059232A1 Methods and compositions for the management of cancer using 2-dg and an igf-ir inhibitor |
| 04/25/2013 | WO2013059222A1 2-pyridyloxy-4-nitrile orexin receptor antagonists |
| 04/25/2013 | WO2013059215A1 Substituted biaryl alkyl amides |
| 04/25/2013 | WO2013059203A1 Novel modified curcumins and their uses |
| 04/25/2013 | WO2013059194A1 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors |
| 04/25/2013 | WO2013059119A1 Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| 04/25/2013 | WO2013059065A1 Methods and compositions for inducing satiety |
| 04/25/2013 | WO2013059064A1 Methods and compositions for inducing satiety |
| 04/25/2013 | WO2013059021A1 2-methylene-vitamin d analogs and their uses |
| 04/25/2013 | WO2013058849A1 Skin therapy systems |
| 04/25/2013 | WO2013058825A1 Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
| 04/25/2013 | WO2013058774A1 Compositions comprising ascorbic acid and an imaging agent and related methods |
| 04/25/2013 | WO2013058751A1 Cellulose derivatives for enhancing bioavailability of flavonoids |
| 04/25/2013 | WO2013058721A1 Pharmaceutical granules and production method |
| 04/25/2013 | WO2013058691A1 Method for inhibition of deubiquitinating activity |
| 04/25/2013 | WO2013058681A2 Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof |
| 04/25/2013 | WO2013058674A1 Bicarbonate haemodialysis solution |
| 04/25/2013 | WO2013058644A1 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes |
| 04/25/2013 | WO2013058643A1 Use of derivatives of betanidine and isobetanidine for the preparation of a drug for the treatment of prediabetes and diabetes |
| 04/25/2013 | WO2013058642A1 Use of betaxanthins and derivatives thereof for the preparation of a drug for the treatment of prediabetes and diabetes |
| 04/25/2013 | WO2013058632A2 Composition containing ohioensins f as a polytrichastrum alpinum-derived novel compound for preventing or treating arteriosclerosis |
| 04/25/2013 | WO2013058631A2 Diterpene furanoids compound which inhibits protein tyrosine phosphatase 1b and the use thereof |
| 04/25/2013 | WO2013058630A2 Composition containing stereocalpin a as a novel compound for preventing or treating arteriosclerosis |
| 04/25/2013 | WO2013058627A2 Composition including rebamipide as an active ingredient for preventing or treating obesity |
| 04/25/2013 | WO2013058613A2 2-hydroxyarylamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for preventing or treating cancer containing same as active ingredient |
| 04/25/2013 | WO2013058605A1 Pharmaceutical composition comprising fluoxetine as an active ingredient, for preventing or treating blood-brain barrier disorders |
| 04/25/2013 | WO2013058579A1 Sirt 1 activator including syringaresinol |
| 04/25/2013 | WO2013058578A2 System for screening skin-whitening material |
| 04/25/2013 | WO2013058527A2 Combined formulation of leukotriene antagonist and epinastine |
| 04/25/2013 | WO2013058511A2 Method for preparing high-purity montelukast sodium salt |
| 04/25/2013 | WO2013058484A2 Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same |
| 04/25/2013 | WO2013058450A1 Stabilized eperisone medical composition, and sustained-release preparation containing same |
| 04/25/2013 | WO2013058441A1 Non-genetic antibiotic resistant inhibitor |
| 04/25/2013 | WO2013058411A1 Solution for oral administration |
| 04/25/2013 | WO2013058409A1 Sustained-release preparation |
| 04/25/2013 | WO2013058361A1 Crystals of androgen receptor antagonist compound |
| 04/25/2013 | WO2013058344A1 Method for predicting effect of plk1 inhibitor |
| 04/25/2013 | WO2013058303A1 Medicinal composition |
| 04/25/2013 | WO2013058294A1 Therapeutic agent for pancreatic cancer and/or biliary tract cancer |
| 04/25/2013 | WO2013058258A1 Bicyclic heterocyclic compound |
| 04/25/2013 | WO2013058194A1 Srf signal activating agent |